The Optimal Management for People with Acute Stroke and Minor Deficits: Intravenous Thrombolysis or Medical Management?

Thromb Haemost. 2023 Jul;123(7):666-668. doi: 10.1055/a-2077-5642. Epub 2023 Apr 19.

Authors

Alan Charles Cameron¹, Azmil H Abdul-Rahim^{2

3}

Affiliations

¹ School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
² Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
³ Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom.

PMID: 37075783
DOI: 10.1055/a-2077-5642

No abstract available

MeSH terms

Brain Ischemia* / drug therapy
Fibrinolytic Agents / adverse effects
Humans
Stroke* / drug therapy
Thrombolytic Therapy
Tissue Plasminogen Activator / therapeutic use
Treatment Outcome

Substances

Tissue Plasminogen Activator
Fibrinolytic Agents